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ABSTRACT 
Objective:  The objective of the study is to assess the effect of blood pressure lowering with Candesartan in 
patients with stroke and elevated blood pressure admitted in this hospital. 
Study Design:  Prospective descriptive observational study. 
Setting:  Neurosurgery, Medical Emergency / OPD, Lady Reading Hospital, Peshawar. 
Materials and Methods:  This descriptive study was done at the Department of Medicine and Neurosurgery, 
Postgraduate Medical Institute, Lady Reading Hospital Peshawar from January 2013 to May 2014 (for One year 
and 5 months period) in a total of 357 patients. In this descriptive study, patients presenting to Emergency 
department or OPD with stroke and elevated blood pressure, presenting within 30 hours of symptom onset and 
with SBP ≥ 140 mmHg, diastolic > 90 mmHg, were eligible for inclusion. Exclusion criteria were contraindicat-
ions to or ongoing treatment with an angiotensin receptor blocker, markedly reduced consciousness, patients with 
chronic heart failure and intolerance to ACE inhibitors, patient unavailability for follow-up and pregnancy or 
breast – feeding. The acute phase treatment was a fixed dose of 4 mg on day 1, 8 mg on day 2 and 16 mg on days 
3 to 7. Blood pressure was measured daily with the patient in the supine position using a blood pressure monitor. 
All patients were follow-up on day 7 and at 1 and 6 months after discharged from hospital. 
Results:  Among 357 cases, 68.06% were males and 31.93% females. Majority (37.25%) belongs to age group of 
61 – 70 years. Out of these, 66.10% patients were found to have ischemic and 33.89% patients had hemorrhagic 
stroke. Highest (40.05%) patients belonged to severe hypertensive group i.e. ≥ 180/110 mmHg. Target was 
achieved in 75.91% patients. 
Conclusions:  Our data suggests that lowering BP in acute ICH is probably safe; however, it remains to be seen 
if this decreases hematoma expansion or improves outcome. 
Key Words:  Stroke; hypertension; Candesartan. 
Abbreviations:  TIA = Transient Ischemic Attack. INTERACT = Intensive Blood Pressure Reduction in Acute 
Cerebral Hemorrhage Trial. SCAST = Scandinavian Candesartan Acute Stroke. 
 
INTRODUCTION 
Stroke is a leading cause of morbidity and mortality 
worldwide.
1,2
 The estimated annual incidence of stroke 
in Pakistan is 250 per 100,000 population, which is 
projected to an estimate of 350,000 new cases every 
year.
3
 A local study conducted in the urban slums of 
Karachi (the largest metropolitan city of Pakistan) esti-
mated a 21.8% life – time prevalence of stroke and/or 
transient ischemic attack (TIA) in individuals aged 
35 years and older.
4
 
 Chronically elevated blood pressure (BP), so-
called ‘hypertension’, is the predominant underlying 
risk factor for stroke.
5
 
 Its frequency varies across studies due to vari-
ability in patient characteristics, settings and criteria 
used to define hypertension, but a systematic review of 
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18 observational studies reported a 53% frequency of 
hypertension (systolic BP, 150 – 200 mmHg) in the 
setting of acute stroke.
6
 More impressive was a study 
which reported a 63% overall frequency of systolic BP 
>140 mmHg among 563,704 patients with acute stroke 
attending emergency departments across the United 
States.
7
 
 Up to 80% of patients have systolic blood pressure 
(SBP) ≥ 140 mmHg at the time of hospital admission. 
A spontaneous fall is observed in most patients within 
10 – 14 days.8-10 
 The angiotensin receptor type 1 blocker cande-
sartan was used in the ACCESS study, including 339 
hypertensive patients (BP > 200 systolic and/or > 110 
diastolic pressure) within 30 hours (median) after stro-
ke. Although no effect on death or disability (primary 
outcome) was seen, the number of deaths and vascular 
events at 1 year were significantly fewer among can-
desartan – treated patients.11 
 The results of three large randomized clinical trials 
on blood pressure lowering in acute stroke-the Chinese 
Antihypertensive Trial in Acute Ischaemic Stroke,
12
 
the Intensive Blood Pressure Reduction in Acute Cere-
bral Hemorrhage Trial (INTERACT2),
13
 and the Scan-
dinavian Candesartan Acute Stroke Trial (SCAST) 
suggest that treatment should differ according to the 
type of stroke.
14
 
 The Scandinavian Candesartan Acute Stroke Trial 
(SCAST), which involved 2029 patients with acute 
stroke (IS and ICH) and a systolic BP > 140 mmHg 
within 30 hours (mean time 18 hours) of symptoms 
onset, randomly allocated to candesartan or placebo, 
achieved a modest mean systolic BP difference of 5 
mmHg (p < 0.0001) between groups over 7 days but 
no difference in functional outcome or vascular events 
between groups at 6 months.
14
 
 The rationale of the study was to assess the effect 
of blood pressure lowering with Candesartan in pati 
ents with stroke and elevated blood pressure admitted 
in this hospital. 
 
MATERIALS AND METHODS 
This descriptive study was done at the Department of 
Medicine and Neurosurgery, Postgraduate Medical 
Institute, Lady Reading Hospital Peshawar from Jan 
uary 2013 to May 2014 (for One year and 5 months 
period) in a total of 357 patients. 
 
Inclusion Criteria 
All patients presenting to Emergency department or
OPD with acute stroke and elevated blood pressure, 
aged 21 years or older, with a clinical diagnosis of str 
oke (ischemic or hemorrhagic), presenting within 30 
hours of symptom onset and with SBP ≥ 140 mmHg, 
diastolic > 90 mmHg, were eligible for inclusion. 
 
Exclusion Criteria 
1. Contraindications to or ongoing treatment with an 
angiotensin receptor blocker 
2. Markedly reduced consciousness 
3. Patients with chronic heart failure and 
4. Intolerance to ACE inhibitors, 
5. Patient unavailability for follow-up and 
6. Pregnancy or breast – feeding. Written, informed 
consent was sought from all patients or their rela-
tives. 
 
Procedure 
The acute phase treatment was a fixed dose of 4 mg on 
day 1, 8 mg on day 2 and 16 mg on days 3 to 7. Pati-
ent’s compliance was assessed by frequent daily recor-
dings of the doses that the patients received. Blood 
pressure was measured frequently daily during the 
morning round with the patient in the supine position 
using a blood pressure monitor. Dose adjustments 
were made if SBP was below 120 mmHg or when cli-
nically indicated. All patients received standard treat-
ment, and therapeutic agents other than angiotensin 
receptor blockers could be administered at investiga-
tors’ discretion, including additional anti-hypertensive 
drugs in case of severe and sustained hypertension. All 
patients were advised to visits in the follow-up period 
on day 7 and at 1 and 6 months after discharge from 
hospital. All these information and bio – data includ-
ing age, gender, hospital course and follow up was 
recorded. 
 
Statistical Analysis 
All the qualitative variables like history of hypertens-
ion, drug, and death, were analyzed for descriptive 
statistics. The frequencies / percentages of these vari-
ables were calculated. For quantitative variables for 
example age, BP levels at various occasions, mean ± 
standard deviation was calculated. For sex distribution, 
male to female ratio was calculated. All the data was 
analyzed in computer program SPSS version 12 for 
windows. 
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RESULTS 
Sex Incidence 
A total of 357 patients including 68.06% males and 
31.93% females were studied according to age, type of 
stroke, and level of blood pressure. Maximum number 
of patients (37.25%) belongs to age group of 61 – 70 
years with mean age of 65 years (Table 1). 
 
Clinical Presentation 
On the basis of type of stroke, 66.10% patients were 
found to have ischemic and 33.89% patients had hem-
orrhagic stroke. 
 
Blood Pressure 
The patients were divided into five categories accord- 
ing to level of blood pressure and highest number of 
patients (40.05%) belonged to severe hypertensive
 
Table 1: Various Characteristics of Patients 
 (n = 357). 
 
Demographic Data No. of Cases Percentage 
Gender Distribution: 
Male 
Female 
 
243 
114 
 
68.06% 
31.93% 
Age: 
21 – 30 years 
31 – 40 years 
41 – 50 years 
51 – 60 years 
61 – 70 years 
71 – 80 years 
81 – 90 years 
 
  11 
  23 
  37 
  44 
133 
  68 
  41 
 
03.08% 
06.44% 
10.36% 
12.32% 
37.25% 
19.04% 
11.48% 
 
 
group i.e. ≥ 180/110 mmHg. Out of 357 hyper-
tensive patients with stroke, target was achieved 
in 75.91% patients (Table 2). 
 
DISCUSSION 
Hypertension is common immediately after 
acute ischemic stroke mainly due to altered 
brain auto regulation. In Pakistan, evidence 
based paradigm is still in its infancy and most 
of the hospitals do not have stroke protocols or 
clinical care pathways for acute stroke manage-
ment. Moreover, the choice of antihypertensive 
therapy for both primary and secondary preven-
tion of stroke may lack the necessary evidence 
base.
15,16
 
 A study highlighted the enormous burden 
of hypertension in the country. Twenty – two 
percent of the urban Pakistani population over 
the age of 15 years, and a third of those aged 45 
years and above, had hypertension.
17
 The Nat-
ional Health Survey of Pakistan (NHSP) (1990-
4) also showed that > 70% of all hypertensive 
patients (85% in rural areas) in Pakistan are
 
Table 2: Types of Stroke, Blood Pressure Levels, and Effect 
of Therapy in Patients (n = 357). 
 
Findings No. of Cases Percentage 
Type of Stroke: 
Ischemic 
Hemorrhagic 
 
268 
  89 
 
75.07% 
24.93% 
Blood Pressure Levels: 
Normal < 130/85 
Prehypertension-130-139/85-89 
Stage I-140-159/90-99 
[Moderate 160-179/100-109 
Stage II  < 
[Severe > 180 / > 110 
 
  25 
  64 
  77 
  48 
143 
 
 
07.00% 
17.92% 
21.56% 
13.44% 
40.05% 
 
Effect of Drug: 
Successful criteria 
Un-successful criteria 
 
271 
  86 
 
75.91% 
24.08% 
 
unaware of their disease, despite the fact that the 
average number of annual visits to the healthcare pro-
vider is 5.8 for women and 4.9 for men. This suggests 
that factors other than poor access to healthcare provi-
ders contribute to the lack of awareness and lack of 
control of hypertension in Pakistan.
18
 
 In a recent study the mean age was 62.0 years; 
64.0% of participants were men, 49.1% were taking 
antihypertensive medication at admission, and 77.9% 
had strokes of thrombotic subtype.
19
 In our study pati-
ents’ mean age was 65 years and majority (68.06%) of 
patients were males. The male preponderance have 
also been reported in many local and international stu-
dies, which may be due to the reason that in this male 
oriented society females are not given preference to 
get medical treatment from male doctors even though 
they may die in homes untreated. 
 Hypertension is the single most important modifi-
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able risk factors for both ischemic and hemorrhagic 
strokes. In one local study majority (66.10%) of pati-
ents had ischemic stroke. In another local study ische-
mic stroke constituted 44 (50%), intra-cerebral hemor-
rhage 26 (29.5%) and subarachnoid hemorrhage 10 
(11.3%) cases.
20
 Similarly in our study majority pati-
ents (68.06%) had ischemic stroke and 31.93% had 
hemorrhagic stroke which are in accordance with the 
above cited local studies. 
 In our study we have included all (100%) stroke 
patients with hypertension while in one local study, 
hypertension was the most common risk factor for 
stroke. Majority (75%) stroke patients were hyperten-
sive.
20
 
 Hypertension is recognized as the most common 
risk factor of stroke in one study. Out of 50 cases, 39 
cases (78%) were hypertensive.
21
 The findings of 
hypertension in the above cited local study replicate 
the findings of hypertension in a study conducted in 
Karachi by Taj F et al,
22
 and also these values regard-
ing hypertension is in near range of studies.
23,24
 
 A large case – control study evaluating risk factors 
for stroke was conducted in Beijing China, has shown 
that 10 risk factors are associated with 90% of the risk 
of stroke and, of these modifiable risk factors, hyper-
tension is the most important for all stroke sub types 
and is a particularly dangerous risk factor for intra-
cerebral hemorrhage.
25
 This study showed that many 
strokes can be predicted and that relatively simple 
measures, such as blood pressure control, could reduce 
the burden of disease. It can be modified with generic 
medications, and it can also be modified at the popu-
lation level by implementing such policies as those 
aimed at reducing salt intake, losing weight and enco-
uraging exercise. 
 Both ischemic and hemorrhagic stroke has strong 
gradients with blood pressure. For each rise of 20 mm-
Hg in systolic blood pressure, the relative risk of is-
chemic and hemorrhagic stroke increases 2.23 and 
3.18 times, respectively. Fall in blood pressure obser-
ved over the 20
th
 century may lead to bigger reduction 
in the incidence of hemorrhagic stroke compared with 
ischemic stroke.
26
 In our study we found that majority 
of our patients with stroke were in the severe blood 
pressure level group i.e. ≥ 180/ ≥ 110 mmHg. 
 In this study we treated our hypertensive patients 
with stroke with Candesartan and it was found succe-
ssful in majority (75.91%) patients which are in con-
trast to a study which found that the overall result of 
SCAST was neutral, and they found no beneficial 
effect of blood pressure lowering treatment with the 
angiotensin receptor blocker candesartan in patients 
with acute stroke and elevated blood pressure. 
 A meta – analysis of randomized – controlled tri-
als with more than 100 patients which have assessed 
the effect of blood pressure lowering treatment in 
acute stroke on death or dependency. The addition of 
the SCAST data did not materially alter the results of 
the meta-analysis and overall, there was no evidence 
of a beneficial treatment effect on functional out-
come.
27
 These results are also in line with the results 
of the latest Cochrane review.
28
 Contrary results to our 
study could be due to varied study’s designs and sam-
ple size selection in the above cited studies. 
 
CONCLUSIONS 
The management of hypertension in the setting of str-
oke is a clinical problem. Our data suggests that lower-
ing BP in acute ICH is probably safe; however, it re-
mains to be seen if this decreases hematoma expansion 
or improves outcome. As blood pressure management 
in acute ischemic stroke remains problematic and it 
should be decided timely as when to start antihyper-
tensives and by how much to reduce BP. Lowering BP 
is effective for recurrent stroke prevention. 
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